CAS
RPRX icon

Coppell Advisory Solutions’s Royalty Pharma RPRX Stock Holding History

Coppell Advisory Solutions’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$2.53K – 1529
2024
Q4 		$2.53K Buy
+100
New +$2.65K ﹤0.01% 1498

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Coppell Advisory Solutions's RPRX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 100 shares — an estimated $2.53K sold.

Coppell Advisory Solutions first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $2.53K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 100 Royalty Pharma shares in Q1 2025, an estimated $2.53K.
  • Coppell Advisory Solutions first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
  • Coppell Advisory Solutions's Royalty Pharma position peaked at $2.53K in Q4 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.